{"filing":{"accession_number":"0001104659-26-116748","cik":"0001818844","ticker":"DWTX","company_name":"Dogwood Therapeutics, Inc.","form":"8-K","filing_date":"2026-10-19","report_date":"2026-10-19","primary_document":"dwtx-20261019x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1818844/000110465926116748/dwtx-20261019x8k.htm"},"events":[{"id":35980,"run_id":33169,"accession_number":"0001104659-26-116748","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Dogwood Therapeutics entered into a Subscription Agreement to issue 4,098,360 shares of common stock at $1.22 per share in a private placement with Sealbond (a subsidiary of CK Life Sciences), raising approximately $5 million. The unregistered shares are sold under Section 4(a)(2) of the Securities Act and Regulation D, materially diluting existing shareholders' ownership and representing a significant capital raise for the development-stage biopharmaceutical company.","company_name":"Dogwood Therapeutics, Inc.","ticker":"DWTX","filing_date":"2026-10-19","form":"8-K","submitted_at":null,"items":[{"id":40236,"accession_number":"0001104659-26-116748","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Dogwood entered into a Subscription Agreement to issue 4,098,360 shares of common stock at $1.22 per share in a private placement with Sealbond (a subsidiary of CK Life Sciences), raising approximately $5 million. The shares are unregistered and sold in reliance on Section 4(a)(2) of the Securities Act and Regulation D, which is the hallmark of a private placement. This is a dilutive equity issuance to an affiliate (Sealbond already owns 63.9% of outstanding shares) that materially affects shareholder ownership and is a significant capital raise for the development-stage biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T12:46:42.737182+00:00","company_name":"","ticker":null,"filing_date":""},{"id":40237,"accession_number":"0001104659-26-116748","item_number":"3.02","item_title":"Unregistered Sale of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Dogwood Therapeutics disclosed a $5 million private placement of 4,098,360 shares of common stock at $1.22 per share to CK Life Sciences, the company's largest shareholder. The shares are unregistered and offered under Section 4(a)(2) of the Securities Act and Regulation D, which is the classic structure for a dilutive private equity issuance. This is material to investors as it represents significant equity dilution and is a key capital-raising event for a development-stage biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T12:46:42.737182+00:00","company_name":"","ticker":null,"filing_date":""},{"id":40238,"accession_number":"0001104659-26-116748","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Dogwood announced a $5 million private placement of 4,098,360 shares of common stock at $1.22 per share to CK Life Sciences, its largest shareholder. The shares are being offered under Section 4(a)(2) of the Securities Act and Regulation D, constituting an unregistered equity issuance. This is a classic dilutive private placement that materially affects existing shareholders' ownership percentages and is a strong signal of capital-raising activity typical of development-stage biopharmaceutical companies.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T12:46:42.737182+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40236,"accession_number":"0001104659-26-116748","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Dogwood entered into a Subscription Agreement to issue 4,098,360 shares of common stock at $1.22 per share in a private placement with Sealbond (a subsidiary of CK Life Sciences), raising approximately $5 million. The shares are unregistered and sold in reliance on Section 4(a)(2) of the Securities Act and Regulation D, which is the hallmark of a private placement. This is a dilutive equity issuance to an affiliate (Sealbond already owns 63.9% of outstanding shares) that materially affects shareholder ownership and is a significant capital raise for the development-stage biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T12:46:42.737182+00:00","company_name":"Dogwood Therapeutics, Inc.","ticker":"DWTX","filing_date":"2026-10-19"},{"id":40237,"accession_number":"0001104659-26-116748","item_number":"3.02","item_title":"Unregistered Sale of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Dogwood Therapeutics disclosed a $5 million private placement of 4,098,360 shares of common stock at $1.22 per share to CK Life Sciences, the company's largest shareholder. The shares are unregistered and offered under Section 4(a)(2) of the Securities Act and Regulation D, which is the classic structure for a dilutive private equity issuance. This is material to investors as it represents significant equity dilution and is a key capital-raising event for a development-stage biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T12:46:42.737182+00:00","company_name":"Dogwood Therapeutics, Inc.","ticker":"DWTX","filing_date":"2026-10-19"},{"id":40238,"accession_number":"0001104659-26-116748","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Dogwood announced a $5 million private placement of 4,098,360 shares of common stock at $1.22 per share to CK Life Sciences, its largest shareholder. The shares are being offered under Section 4(a)(2) of the Securities Act and Regulation D, constituting an unregistered equity issuance. This is a classic dilutive private placement that materially affects existing shareholders' ownership percentages and is a strong signal of capital-raising activity typical of development-stage biopharmaceutical companies.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T12:46:42.737182+00:00","company_name":"Dogwood Therapeutics, Inc.","ticker":"DWTX","filing_date":"2026-10-19"}]}